ArticleBMC biotechnology2014
Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies.
Article in BMC biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Preparation of Monoclonal Antibodies Against Porcine Circovirus Type 2 Capsid Protein and Development of a Blocking ELISA for Detection of the Antibody Against the Virus.Veterinary sciences · 2026Article
- Development of recombinant capsid protein-based single serum dilution ELISA for sero-detection of porcine circovirus type 2 infection in pigs.Veterinary research communications · 2024Article
- Recombinantly expressed virus-like particles (VLPs) of canine circovirus for development of an indirect ELISA.Veterinary research communications · 2024Article
- Generation of porcine circovirus type 4 virus-like particles and their use to detect serum antibodies.Archives of virology · 2024Article
- Implementation of point-of-care platforms for rapid detection of porcine circovirus type 2.Journal of veterinary science · 2024Article
- Production of virus-like particles of porcine circovirus 2 in baculovirus expression system and its application for antibody detection.BMC veterinary research · 2023Article
- Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery.Vaccines · 2023Review
- Self-Assembly of Porcine Parvovirus Virus-like Particles and Their Application in Serological Assay.Viruses · 2022Article
- Genetic Diversity of Porcine Circovirus Types 2 and 3 in Wild Boar in Italy.Animals : an open access journal from MDPI · 2022Article
- The truncated form of flagellin (tFlic) provides the 2dCap subunit vaccine with better immunogenicity and protective effects in mice.Animal diseases · 2022Article
- BioprospectingFrontiers in bioengineering and biotechnology · 2022Review
- Self-assembly into virus-like particles of the recombinant capsid protein of porcine circovirus type 3 and its application on antibodies detection.AMB Express · 2020Article
- Comparison of Multiplex Real-Time PCR and PCR-Reverse Blot Hybridization Assays for the Direct and Rapid Detection of Porcine Circovirus Type 2 Genotypes.Frontiers in veterinary science · 2020Article
- Immunogenicity of plant-produced porcine circovirus-like particles in mice.Plant biotechnology journal · 2019Article
- Review
- Preparation of virus-like particles for porcine circovirus type 2 by YeastFab Assembly.Virus genes · 2018Article
- The evidence of occurrence of porcine circovirus 2 isolation and characterization in Kazakhstan.Virusdisease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPorcine circovirus type 2 (PCV2) is considered to be an important emerging pathogen associated with a number of different syndromes and diseases in pigs known as PCV2-associated diseases. It has been responsible for significant mortality among pigs and remains a serious economic problem to the swine industry worldwide leading to significant negative impacts on profitability of pork production.
resultsIn this study we have demonstrated that PCV2 capsid (Cap) protein based virus-like particles (VLPs) were efficiently produced in yeast S. cerevisiae and induced production of monoclonal antibodies (MAbs) reactive with virus-infected cells. Moreover, PCV2 Cap VLPs served as a highly specific recombinant antigen for the development of an indirect IgG PCV2 Cap VLP-based ELISA for the detection of virus-specific IgG antibodies in swine sera. Four hundred-nine serum samples collected from pigs in Lithuania were tested for PCV2-specific IgG to determine the sensitivity and specificity of the newly developed ELISA in parallel using a commercial SERELISA test as a gold standard. From 409 tested serum samples, 297 samples were positive by both assays. Thirty-nine sera from 112 serum samples were determined as negative by SERELISA but were found to be positive both in the newly developed indirect IgG PCV2 Cap VLP-based ELISA and the PCR test.
conclusionsWe have demonstrated that S. cerevisiae expression system is an alternative to insect/baculovirus expression system for production of homogenous in size and shape PCV2 Cap protein-based VLPs similar to native virions. Yeast expression system tolerated native virus genes encoding PCV2 Cap protein variants as well as the codon-optimized gene. Moreover, yeast-derived PCV2 Cap VLPs were capable to induce the generation of PCV2-specific MAbs that did not show any cross-reactivity with PCV1-infected cells. The high sensitivity and specificity of the indirect IgG PCV2 Cap VLP-based ELISA clearly suggested that this assay is potentially useful diagnostic tool for screening PCV2-suspected samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.